Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled mRNA Immunotherapy in Advanced Solid Tumors
NCT07657611Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2026
- Primary completion
- Dec 2026
01
Overview
Phase 1, open-label, single-arm trial in lung cancer and solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Safety and Tolerability. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
lung cancersolid tumor
Beyond the preview
Go deeper on NCT07657611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657611.